A Phase 4, Open Label Field Study to Evaluate the Clinical Benefit, Safety, and Pharmacokinetics of Anthim (Obiltoxaximab) When Used in the Treatment of Suspected, Probable, or Confirmed Cases of Inhalational Anthrax Due to B. Anthracis

Trial Profile

A Phase 4, Open Label Field Study to Evaluate the Clinical Benefit, Safety, and Pharmacokinetics of Anthim (Obiltoxaximab) When Used in the Treatment of Suspected, Probable, or Confirmed Cases of Inhalational Anthrax Due to B. Anthracis

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Obiltoxaximab (Primary)
  • Indications Anthrax
  • Focus Therapeutic Use
  • Sponsors EluSys Therapeutics
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 1 Apr 2021 to 1 Jan 2021.
    • 25 Jul 2017 Planned primary completion date changed from 1 Apr 2021 to 1 Jan 2021.
    • 25 Jul 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top